Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

Aurobindo Pharma Limited's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 16.41163
debtToEquity 27.28600
earningsGrowth -0.09200
revenueGrowth 0.08500
grossMargins 0.57822
operatingMargins 0.15157
trailingEps 59.86000
forwardEps 62.29000

With AUROPHARMA's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
AUROPHARMA's low Debt-to-Equity ratio shows that the company avoids excessive reliance on debt, reducing financial risk. This suggests a more secure financial position with less vulnerability to debt-related risks, making AUROPHARMA a stable and conservative investment.
With both earnings and revenue growth in low territory, AUROPHARMA is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
AUROPHARMA's negative gross and operating margins indicate that the company is operating at a loss. This reflects an inability to cover production costs and operational expenses, which could undermine its financial stability.
Aurobindo Pharma Limited's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that Aurobindo Pharma Limited's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

Over time, AUROPHARMA's price projections have steadily declined, reflecting reduced confidence in the company's future performance. The downward revisions suggest analysts are becoming more conservative in their assessments.

Insider Transactions:

Insider Transactions for AUROPHARMA
Insider Transactions for AUROPHARMA


Recent trading of Aurobindo Pharma Limited stock saw 9 sales, with market price at 1027.683329264323 per share.During the period under consideration, there were no sell transactions.With more buying than selling around AUROPHARMA's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


AUROPHARMA has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see AUROPHARMA as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.